Biomarkers in Tissue Samples From Patients With Ductal Breast Carcinoma in Situ
Recruitment status was Not yet recruiting
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
PURPOSE: This research study is studying biomarkers in tissue samples from patients with ductal breast carcinoma in situ.
Genetic: RNA analysis
Genetic: gene expression analysis
Genetic: reverse transcriptase-polymerase chain reaction
Other: laboratory biomarker analysis
|Official Title:||A Correlative Science Study for ECOG E5194|
- Ipsilateral local failure (first event of invasive or ductal carcinoma in situ [DCIS] recurrence) [ Designated as safety issue: No ]
- Contralateral breast cancer (invasive or DCIS) [ Designated as safety issue: No ]
|Study Start Date:||June 2010|
|Estimated Primary Completion Date:||April 2011 (Final data collection date for primary outcome measure)|
- To validate the prognostic utility of the Oncotype DX Recurrence Score® assay in tissue samples from patients with ductal breast carcinoma in situ enrolled on clinical trial ECOG-E5194.
OUTLINE: RNA extracted from archived tissue samples are analyzed for gene expression profile by Oncotype DX Recurrence Score® assay (a reverse transcriptase-PCR-based assay).
Please refer to this study by its ClinicalTrials.gov identifier: NCT01132560
|Principal Investigator:||Lawrence J. Solin, MD, FACR||Abramson Cancer Center of the University of Pennsylvania|